Structure Therapeutics (NASDAQ:GPCR) Shares Up 10.9% – Should You Buy?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares traded up 10.9% during mid-day trading on Wednesday . The stock traded as high as $43.00 and last traded at $44.79. Approximately 202,690 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 884,261 shares. The stock had previously closed at $40.38.

More Structure Therapeutics News

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: Citizens JMP reaffirmed its “Market Outperform” rating and set a $110 price target, implying substantial upside from recent trading levels. The bullish view reflects the potential of Structure’s oral obesity-treatment pipeline. Benzinga analyst rating report
• Positive Sentiment: Structure reported encouraging clinical updates for its oral small-molecule programs. Aleniglipron, an oral GLP-1 agonist, produced up to a 16.2% mean reduction in body weight at 72 weeks, with no observed plateau and fewer than 5% of patients discontinuing because of adverse events in the ACCESS open-label extension study. Structure Therapeutics clinical data release
• Positive Sentiment: The company’s oral amylin candidate ACCG-2671 showed a roughly six-day half-life, evidence of target engagement and up to 3.3% body-weight loss in an early Phase 1/2a study, with no serious adverse events reported. The multiple-dose portion has begun, although results are not expected until the first half of 2027. RTTNews clinical data report
• Neutral Sentiment: Phase 3 enrollment for aleniglipron is continuing, but topline results are not expected until the second half of 2028. This leaves significant execution and clinical-development risk before potential commercialization. Seeking Alpha conference-call transcript
• Negative Sentiment: Despite the positive headline data, the stock declined in reaction to the obesity-drug update, suggesting investors may have viewed the results as insufficiently differentiated or focused on the early-stage status and lengthy timeline of the programs. Seeking Alpha market reaction report

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Citizens Jmp reissued a “market outperform” rating and issued a $110.00 price objective on shares of Structure Therapeutics in a research report on Wednesday. Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday. Finally, Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Stock Up 7.3%

The company has a market cap of $3.02 billion, a price-to-earnings ratio of -43.18 and a beta of -1.45. The business has a fifty day simple moving average of $50.41 and a 200 day simple moving average of $49.01.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC purchased a new position in Structure Therapeutics in the first quarter valued at about $28,000. State of Wyoming acquired a new stake in shares of Structure Therapeutics in the 2nd quarter worth approximately $28,000. CWM LLC increased its stake in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. IFP Advisors Inc acquired a new position in Structure Therapeutics during the second quarter worth $46,000. Finally, Assetmark Inc. boosted its position in Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after purchasing an additional 449 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.